In Switzerland, the median time from first submission by a pharmaceutical company to availability of a medicinal product to patients is almost 650 days.
Interpharma members currently invest around CHF 6.5 billion a year in research and development in Switzerland.
show more articles
In just a few years, Switzerland has fallen from first to fifth place in the Global Competitiveness Index (2019).
are numerous diseases that often used to prove serious or fatal for patients, for example hepatitis C, thanks to innovative medicines.
The pharmaceutical industry in Switzerland will also need attractive framework conditions in future, including legal certainty, open export markets and the availability of labour.
People in Switzerland benefit from access to high-quality healthcare provision. However, there is still a need for action and improvement in various areas.
Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.
Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.
Information on our key figures and activities in the financial year 2020
More about the tasks and overriding aims of Interpharma
Latest information and media contacts for media representatives